reason report
oral cgrp look pretti gate
bottom line believ oral cgrp done well
first quarter launch even environ
shown iqvia data close track remain
optimist biohaven gain traction lean
virtual outreach dtc kick
allergan mp ubrelvi market month
strong launch far even amidst
week april base iqvia data estim sale week
annual run rate assum gross-to-net
estim sale exclud type inventori build
channel appear quit strong first quarter
product launch view
biohaven op nurtec market
one month launch far respect especi
given current difficult environ product launch
week april base iqvia data estim sale week
annual run rate estim base
nrx biohaven taken market share allergan far
key advantag biohaven start kick abl
launch dtc advertis tv ahead allergan dtc launch
past week probabl alreadi play role
environ sale rep abl engag physician
person model assum sale
conserv covid environ line
consensu sale accord factset accord
unlik two cgrp lilli reyvow slow launch
surpris given physician feedback side
effect concern dizzi real problem week april
base iqvia data estim sale week
insid iqvia data tracker ubrelvi nurtec
pleas refer page import disclosur price chart analyst certif
iqvia ubrelvi nurtec nrx data
compani report svb leerink estim iqvia data april
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori abbvi inc
leerink initi coverag market perform rate octob
creat bluematrix
price target base simpl averag three approach believ reason
basi valu stock today approach simpl price earn multipl compar larg
biopharmaceut compani price sale multipl larg cap peer compani stock discount cash
flow dcf appli peer ep revenu multipl use averag larg cap larg molecul therapeut
compani midterm growth tail risk averag consensu ep
multipl appli current ep estim give valu use
revenu multipl similar compani consensu sale appli revenu estim
give valu lastli dcf valuat given wacc termin cash flow growth
rate begin humira biosimilar entri give present valu averag three
method current price target
risk valuat
risk view outlook valuat includ major chang price outlook reimburs
coverag label competit posit humira compani main product risk includ commerci
develop disappoint compani follow-on program inflammatori diseas imbruvica
venclexta expand hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow dividend
reduct forecast ebitda due neg busi trend would place compani capit alloc
strategi dividend growth risk opportun upsid expect includ stronger-than-expect
price volum share humira emerg tangibl demand underappreci element
compani early-to-mid stage pipelin asset potenti label expans opportun late stage opportun
rate price target histori ltd
creat bluematrix
pt base sotp analysi forecast cash flow discount rate
risk valuat
acut market smaller forecast due lack differenti gener triptan and/or payer
restrict higher expect
rimegep may get approv prevent due unforeseen issu
payer may restrict expect rimegep acut and/or prevent indic
biohaven struggl compet larger competitor allergan lilli choos go alon
investor skeptic glutam pipelin sinc phase trial failur spinocerebellar ataxia
rate price target histori compani
leerink place outperform rate octob
creat bluematrix
sinc suspend coverag share longer put forth valuat
risk valuat
sinc suspend coverag longer put forth risk valuat
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
